Moderna announced that David Berman has been appointed as the company's Chief Development Officer, beginning March 2, 2026. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel. Dr. Jacqueline Miller will step down as Chief Medical Officer and member of the Executive Committee effective the same date and will remain as a consultant to the Company to assist with the transition.

"David's leadership experience in oncology and infectious disease will be critical as we continue to invest and drive innovation across Moderna's pipeline," said Stéphane Bancel, Chief Executive Officer of Moderna. "I look forward to welcoming David to Moderna's Executive Committee as Chief Development Officer and partnering with him to advance our portfolio of mRNA medicines. At the same time, I am deeply grateful for Jackie's leadership and significant contributions over the past five and a half years. She has built a strong foundation and team in infectious disease vaccines at Moderna. The team will continue to drive toward a bright future with three approved vaccines, three more in Phase 3 or filed for approval, and an exciting early pipeline. I wish Jackie all the best in her next chapter."

Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics. He most recently served as EVP and Head of Research and Development at Immunocore, where he led the development and approval of the first T cell receptor therapeutic. Prior to Immunocore, Dr. Berman served as SVP and Head of AstraZeneca's Immuno-oncology (IO) franchise, responsible for strategy and execution of a broad IO portfolio. Dr. Berman has also held senior development roles at Bristol-Myers Squibb, including Global Clinical Lead for the first approved IO checkpoint inhibitor and one of the first monoclonal antibodies for multiple myeloma, and served as the head of their early-stage IO portfolio.

Dr. Berman received his M.D. and Ph.D. from the University of Texas Southwestern Medical School. He trained in pathology at the National Cancer Institute, followed by a fellowship at The Johns Hopkins Hospital.